Healthcare provider profile · identity verified

Mary Poole, MD

Internal Medicine · BROOKLYN, NY · NPI 1942296777

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	277	79
Rosuvastatin Calcium	Rosuvastatin Calcium	227	62
Amlodipine Besylate	Amlodipine Besylate	202	51
Losartan Potassium	Losartan Potassium	161	48
Levothyroxine Sodium	Levothyroxine Sodium	147	42
Metformin Hcl	Metformin Hcl	143	43
Metformin Hcl Er	Metformin Hcl	139	35
Simvastatin	Simvastatin	123	35
Olmesartan Medoxomil	Olmesartan Medoxomil	118	31
Albuterol Sulfate Hfa	Albuterol Sulfate	111	35
Metoprolol Succinate	Metoprolol Succinate	100	35
Furosemide	Furosemide	87	23
Zolpidem Tartrate	Zolpidem Tartrate	72	16
Metoprolol Tartrate	Metoprolol Tartrate	71	16
Pantoprazole Sodium	Pantoprazole Sodium	65	17
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	64	12
Omeprazole	Omeprazole	62	16
Lisinopril	Lisinopril	61	16
Gabapentin	Gabapentin	59	16
Montelukast Sodium	Montelukast Sodium	58	15
Eliquis	Apixaban	57	18
Azithromycin	Azithromycin	56	47
Enalapril Maleate	Enalapril Maleate	53	12
Escitalopram Oxalate	Escitalopram Oxalate	53	12
Hydrochlorothiazide	Hydrochlorothiazide	52	15
Pravastatin Sodium	Pravastatin Sodium	50	14
Jardiance	Empagliflozin	48	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	45	17
Vitamin D2	Ergocalciferol (Vitamin D2)	44	suppressed
Carvedilol	Carvedilol	43	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	42	13
Synthroid	Levothyroxine Sodium	41	12
Valsartan	Valsartan	41	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	39	suppressed
Sertraline Hcl	Sertraline Hcl	39	15
Alprazolam	Alprazolam	38	18
Famotidine	Famotidine	38	12
Mirtazapine	Mirtazapine	38	suppressed
Mounjaro	Tirzepatide	37	suppressed
Ezetimibe	Ezetimibe	35	12
Ibandronate Sodium	Ibandronate Sodium	33	11
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	32	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	32	suppressed
Bupropion Xl	Bupropion Hcl	31	suppressed
Atenolol	Atenolol	30	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	29	suppressed
Allopurinol	Allopurinol	28	suppressed
Clonazepam	Clonazepam	28	suppressed
Farxiga	Dapagliflozin Propanediol	28	suppressed
Celecoxib	Celecoxib	26	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	26	suppressed
Irbesartan	Irbesartan	25	suppressed
Citalopram Hbr	Citalopram Hydrobromide	24	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	23	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	23	11
Diclofenac Sodium	Diclofenac Sodium	23	suppressed
Olmesartan-Amlodipine-Hctz	Olmesartan/Amlodipin/Hcthiazid	22	suppressed
Telmisartan	Telmisartan	22	suppressed
Amoxicillin	Amoxicillin	20	14
Duloxetine Hcl	Duloxetine Hcl	20	suppressed
Ropinirole Hcl	Ropinirole Hcl	20	suppressed
Cefdinir	Cefdinir	19	17
Clopidogrel	Clopidogrel Bisulfate	19	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Symbicort	Budesonide/Formoterol Fumarate	19	suppressed
Xarelto	Rivaroxaban	19	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	18	suppressed
Levetiracetam	Levetiracetam	18	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	18	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	18	suppressed
Potassium Chloride	Potassium Chloride	18	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	17	suppressed
Fluticasone Propionate	Fluticasone Propionate	17	suppressed
Glimepiride	Glimepiride	17	suppressed
Alendronate Sodium	Alendronate Sodium	16	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	16	suppressed
Meloxicam	Meloxicam	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Repaglinide	Repaglinide	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Meclizine Hcl	Meclizine Hcl	15	suppressed
Omeprazole-Sodium Bicarbonate	Omeprazole/Sodium Bicarbonate	15	suppressed
Trazodone Hcl	Trazodone Hcl	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	12
Rybelsus	Semaglutide	14	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	13	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	13	suppressed
Folic Acid	Folic Acid	13	suppressed
Incruse Ellipta	Umeclidinium Bromide	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Acyclovir	Acyclovir	12	suppressed
Benazepril Hcl	Benazepril Hcl	12	suppressed
Digoxin	Digoxin	12	suppressed
Fosinopril Sodium	Fosinopril Sodium	12	suppressed
Latanoprost	Latanoprost	12	suppressed
Timolol Maleate	Timolol Maleate	12	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	12	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	11	suppressed
Carvedilol Er	Carvedilol Phosphate	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	11	suppressed
Labetalol Hcl	Labetalol Hcl	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Trulicity	Dulaglutide	11	suppressed
Vascepa	Icosapent Ethyl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error